Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study  Dr J Michael Wells, MD, Roopan F Farris, MD, Taylor A Gosdin,

Similar presentations


Presentation on theme: "Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study  Dr J Michael Wells, MD, Roopan F Farris, MD, Taylor A Gosdin,"— Presentation transcript:

1 Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study 
Dr J Michael Wells, MD, Roopan F Farris, MD, Taylor A Gosdin, Mark T Dransfield, MD, Michelle E Wood, BPhty, Prof Scott C Bell, MD, Prof Steven M Rowe, MD  The Lancet Respiratory Medicine  Volume 4, Issue 8, Pages (August 2016) DOI: /S (16) Copyright © 2016 Elsevier Ltd Terms and Conditions

2 Figure 1 Representative measurements of pulmonary artery and ascending aorta diameters in a non-contrast-enhanced CT image The diameters of the pulmonary artery (purple) and ascending aorta (red) were measured at the level of the pulmonary artery bifurcation. The diameter of the ascending aorta was the mean of the two perpendicular measurements. Magnification=1·83×. The Lancet Respiratory Medicine 2016 4, DOI: ( /S (16) ) Copyright © 2016 Elsevier Ltd Terms and Conditions

3 Figure 2 Study flow chart for (A) derivation and (B) validation cohorts TPCH=The Prince Charles Hospital. PA:A=pulmonary artery diameter to ascending aorta diameter ratio. The Lancet Respiratory Medicine 2016 4, DOI: ( /S (16) ) Copyright © 2016 Elsevier Ltd Terms and Conditions

4 Figure 3 Relation between pulmonary artery enlargement and acute pulmonary exacerbations in adults with cystic fibrosis (A) Follow-up at 1 year in the derivation cohort. Follow-up at (B) 1 year and (C) 2 years in the validation cohort. PA:A=pulmonary artery diameter to ascending aorta diameter ratio. Error bars represent 95% CI. The Lancet Respiratory Medicine 2016 4, DOI: ( /S (16) ) Copyright © 2016 Elsevier Ltd Terms and Conditions

5 Figure 4 Time to first acute pulmonary exacerbation in the validation cohort (A) Unadjusted analysis. (B) Analysis adjusted for sex, body-mass index, previous exacerbation, chronic Pseudomonas aeruginosa infection, and FEV1/FVC. FEV1=forced expiratory volume in 1 s. FVC=forced vital capacity. PA:A=pulmonary artery diameter to ascending aorta diameter ratio. The Lancet Respiratory Medicine 2016 4, DOI: ( /S (16) ) Copyright © 2016 Elsevier Ltd Terms and Conditions


Download ppt "Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study  Dr J Michael Wells, MD, Roopan F Farris, MD, Taylor A Gosdin,"

Similar presentations


Ads by Google